T-cell response to cardiac myosin persists in the absence of an alloimmune response in recipients with chronic cardiac allograft rejection

Transplantation

Volumn 74, Issue 7, 2002, Pages 1053-1057

  Rolls, Hillary K ^a   Kishimoto, Koji ^b   Dong, Victor M ^b   Illigens, Ben M W ^a   Sho, Masayuki ^b   Sayegh, Mohamed H ^b   Benichou, Gilles ^a   Fedoseyeva, Eugenia V ^a  

^a SCHEPENS EYE RESEARCH INSTITUTE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GAMMA INTERFERON; MYOSIN;

ALLOTRANSPLANTATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOIMMUNITY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; GRAFT REJECTION; GRAFT SURVIVAL; HEART TRANSPLANTATION; IMMUNE MEDIATED INJURY; IMMUNOLOGICAL TOLERANCE; IMMUNOPATHOGENESIS; MAJOR HISTOCOMPATIBILITY COMPLEX; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE;

EID: 0037108850     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-200210150-00028     Document Type: Article

References (29)

1. Libby P, Pober JS. Chronic rejection. Immunity 2001;14(4):387.
2. Waaga AM, Gasser M, Laskowski I, et al. Mechanisms of chronic rejection. Curr Opin Immunol 2000;12(5):517.
3. Massicot-Fisher J, Noel P, Madsen JC. Recommendations of the National Heart, Lung and Blood Institute Heart and Lung Tolerance Working Group. Transplantation 2001;72(8):1467.
4. Paul LC. Immunologic risk factors for chronic renal allograft dysfunction. Transplantation 2001;71(11 suppl):SS17.
5. Paul WE. Fundamental immunology [ed 3]. New York: Raven Press, Ltd., 1993.
6. Suciu-Foca N, Harris PE, Cortesini R. Intramolecular and intermolecular spreading during the course of organ allograft rejection. Immunol Rev 1998;164:241.
7. Vella JP, Magee C, Vos L, et al. Cellular and humoral mechanisms of vascularized allograft rejection induced by indirect recognition of donor MHC allopeptides. Transplantation 1999;67(12):1523.
8. Lee RS, Yamada K, Houser SL, et al. Indirect recognition of allopeptides promotes the development of cardiac allograft vasculopathy. Proc Natl Acad Sci U S A 2001;98(6):3276.
9. Baker RJ, Hernandez-Fuentes MP, Brookes PA, et al. Loss of direct and maintenance of indirect alloresponses in renal allograft recipients: implications for the pathogenesis of chronic allograft nephropathy. J Immunol 2001;167(12):7199.
10. Ensminger SM, Spriewald BM, Witzke O, et al. Indirect allorecognition can play an important role in the development of transplant arteriosclerosis. Transplantation 2002;73(2):279.
11. Jurcevic S, Ainsworth ME, Pomerance A, et al. Antivimentin antibodies are an independent predictor of transplant-associated coronary artery disease after cardiac transplantation. Transplantation 2001;71(7):886.
12. Joosten SA, van Dixhoorn MG, Borrias MC, et al. Antibody response against perlecan and collagen types IV and VI in chronic renal allograft rejection in the rat. Am J Pathol 2002;160(4):1301.
13. Fedoseyeva EV, Zhang F, Orr PL, et al. De novo autoimmunity to cardiac myosin after heart transplantation and its contribution to the rejection process. J Immunol 1999;162(11):6836.
14. Penninger JM, Pummerer C, Liu P, et al. Cellular and molecular mechanisms of murine autoimmune myocarditis. Apmis 1997;105(1): 1.
15. Fedoseyeva EV, Kishimoto K, Rolls HK, et al. Modulation of tissue-specific immune response to cardiac myosin can prolong survival of allogeneic heart transplants. J Immunol 169(3):1168.
16. Hancock WW, Shi C, Picard MH, et al. LEW-to-F344 carotid artery allografts: analysis of a rat model of posttransplant vascular injury involving cell-mediated and humoral responses. Transplantation 1995;60(12): 1565.
17. Hancock WW, Buelow R, Sayegh MH, et al. Antibody-induced transplant arteriosclerosis is prevented by graft expression of anti-oxidant and anti-apoptotic genes. Nat Med 1998;4(12):1392.
18. Larsen CP, Alexander DZ, Hollenbaugh D, et al. CD40-gp39 interactions play a critical role during allograft rejection. Suppression of allograft rejection by blockade of the CD40-gp39 pathway. Transplantation 1996; 61(1):4.
19. Larsen CP, Elwood ET, Alexander DZ, et al. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature 1996;381(6581):434.
20. Shimizu K, Schonbeck U, Mach F, et al. Host CD40 ligand deficiency induces long-term allograft survival and donor-specific tolerance in mouse cardiac transplantation but does not prevent graft arteriosclerosis. J Immunol 2000;165(6):3506.
21. Ensminger SM, Witzke O, Spriewald BM, et al. CD8+ T cells contribute to the development of transplant arteriosclerosis despite CD154 blockade. Transplantation 2000;69(12):2609.
22. Corry RJ, Winn HJ, Russell PS. Primarily vascularized allografts of hearts in mice. The role of H-2D, H-2K, and non-H-2 antigens in rejection. Transplantation 1973;16(4):343.
23. Kishimoto K, Dong VM, Issazadeh S, et al. The role of CD154-CD40 versus CD28-B7 costimulatory pathways in regulating allogeneic Thl and Th2 responses in vivo. J Clin Invest 2000;106(1):63.
24. Russell ME, Hancock WW, Akalin E, et al. Chronic cardiac rejection in the LEW to F344 rat model. Blockade of CD28-B7 costimulation by CTLA4Ig modulates T cell and macrophage activation and attenuates arteriosclerosis. J Clin Invest 1996;97(3):833.
25. Shiverick KT, Thomas LL, Alpert NR. Purification of cardiac myosin. Application to hypertrophied myocardium. Biochim Biophys Acta 1975; 393(1):124.
26. Williams MA, Trambley J, Ha J, et al. Genetic characterization of strain differences in the ability to mediate CD40/CD28-independent rejection of skin allografts. J Immunol 2000;165(12):6849.
27. Benichou G, Valujskikh A, Heeger PS, Contributions of direct and indirect T cell alloreactivity during allograft rejection in mice. J Immunol 1999; 162(1):352.
28. Matzinger P, Bevan MJ. Hypothesis: why do so many lymphocytes respond to major histocompatibility antigens? Cell Immunol 1977; 29(1):1 29(l):l.
29. Sho M, Sandner SE, Najafian N. et al. New insights into interaction between T cell costimulatory blockade and conventional immunosuppressive drugs. Ann Surg (in press).